Home LiteratureArticle Details
PMID: 16965241 Published · ppublish English Clinical Trial, Phase I Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study.

Nutrition and cancer ·Vol. 55 ·No. 1 ·2006-00-00 ·Pages 53-62

Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P

Abstract

Broccoli sprouts are widely consumed in many parts of the world. There have been no reported concerns with respect to their tolerance and safety in humans. A formal phase I study of safety, tolerance, and pharmacokinetics appeared justified because these sprouts are being used as vehicles for the delivery of the glucosinolate glucoraphanin and its cognate isothiocyanate sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] in clinical trials. Such trials have been designed to evaluate protective efficacy against development of neoplastic and other diseases. A placebo-controlled, double-blind, randomized clinical study of sprout extracts containing either glucosinolates (principally glucoraphanin, the precursor of sulforaphane) or isothiocyanates (principally sulforaphane) was conducted on healthy volunteers who were in-patients on our clinical research unit. The subjects were studied in three cohorts, each comprising three treated individuals and one placebo recipient. Following a 5-day acclimatization period on a crucifer-free diet, the broccoli sprout extracts were administered orally at 8-h intervals for 7 days (21 doses), and the subjects were monitored during this period and for 3 days after the last treatment. Doses were 25 micromol of glucosinolate (cohort A), 100 micromol of glucosinolate (cohort B), or 25 micromol of isothiocyanate (cohort C). The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose). Thirty-two types of hematology or chemistry tests were done before, during, and after the treatment period. Indicators of liver (transaminases) and thyroid [thyroid-stimulating hormone, total triiodothyronine (T3), and free thyroxine (T4)] function were examined in detail. No significant or consistent subjective or objective abnormal events (toxicities) associated with any of the sprout extract ingestions were observed.

MeSH Terms
Adult Anticarcinogenic Agents/metabolism,pharmacokinetics,urine Blood Chemical Analysis Brassica/chemistry Cohort Studies Consumer Product Safety Diet Dose-Response Relationship, Drug Double-Blind Method Female Glucosinolates/metabolism,pharmacokinetics,urine Humans Isothiocyanates/metabolism,pharmacokinetics,urine Liver/enzymology Male Middle Aged Neoplasms Plant Extracts/metabolism,urine Thyroid Hormones/blood
Chemicals
Anticarcinogenic Agents Glucosinolates Isothiocyanates Plant Extracts Thyroid Hormones
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Shapiro Theresa A
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Fahey Jed W
Dinkova-Kostova Albena T
Holtzclaw W David
Stephenson Katherine K
Wade Kristina L
Ye Lingxiang
Talalay Paul
Article Info
Journal
Nutrition and cancer
Abbr.
Nutr Cancer
ISSN
0163-5581
Published
2006-00-00
Pages
53-62
Language
English
Region
United States
NLM ID
7905040
Subset
IM
Grants
NCRR NIH HHS · M01-RR-00052 · United States
NCI NIH HHS · R01 CA093780 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com